XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Total revenue $ 96,844 $ 82,422
Biopharmaceutical revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 953 4,447
Contract manufacturing and testing    
Disaggregation of Revenue [Line Items]    
Total revenue 2,051 1,687
Biopharmaceutical and other revenue    
Disaggregation of Revenue [Line Items]    
Total revenue 3,004 6,134
Other Testing Revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 3,000 $ 2,300